Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study
Status:
Unknown status
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
Neovascular glaucoma is a potentially blinding condition characterized by the growth of
newvessels at the anterior part of the eye. This growth is driven by the overexpression of a
protein called Vascular Endothelial Growth Factor (VEGF). That happens in diseases such as
diabetic retinopathy or venous retinal occlusion, and lead to a fast increase in intraocular
pressure (IOP). Traditional treatment include laser photocoagulation of the retina in order
to decrease VEGF formation. The investigators postulate that the use of anti-VEGF
intravitreal injections may accelerate recovery and decrease the need of surgery in cases of
neovascular glaucoma.